ea0032p845 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013
Sheppard Michael
, Bronstein Marcello
, Freda Pamela
, Serri Omar
, De Marinis Laura
, Naves Luciana
, Rozhinskaya Liudmila
, Hermosillo Resendiz Karina
, Ruffin Matthieu
, Asubonteng Kobby
, Colao Annamaria
Introduction: Pasireotide LAR was significantly superior to octreotide LAR at providing biochemical control in a 12-month trial in 358 medically naïve patients with acromegaly. Patients with clinical benefit or GH <2.5 μg/l and IGF1≤ULN could continue therapy in the extension study.Methods: Patients entering the extension (pasireotide LAR, n=74; octreotide LAR, n=46) were followed up to month 26 (core plus extension)...